Cancer Research Audrey Hepburn  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 3125-3130, June 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pommier, Y.
Right arrow Articles by Riou, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pommier, Y.
Right arrow Articles by Riou, J.-F.

Differential Effects of Amsacrine and Epipodophyllotoxins on Topoisomerase II Cleavage in the Human c-myc Protooncogene

Yves Pommier1, Ann Orr, Kurt W. Kohn and Jean-François Riou

Laboratory of Molecular Pharmacology, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 [Y. P., A. O., K. W. K.], and Rhône-Poulenc Rorer, Centre de Recherche de Vitry-Alfortville, 94403 Vitry-sur-Seine Cedex, France [J-F. R.]

Amsacrine and demethylepipodophyllotoxins (etoposide and teniposide) are potent topoisomerase II inhibitors which have optimum activity in different cancers. To investigate whether these differences are due to different activity on cellular oncogenes, drug-induced topoisomerase II cleavage sites were mapped and sequenced in the human c-myc protooncogene. In the presence of purified murine L1210 topoisomerase II, amsacrine induces prominent cleavage in the P2 promoter (site 2499/2502). Footprinting experiments indicate that topoisomerase II binds to the entire promoter region (~20 base pairs on the sides of the P2 site). In the case of teniposide or etoposide, cleavage is more diffuse and markedly less at the P2 site. Mapping of cleavage sites in human small cell lung carcinoma cells (NCI N417) also shows that cleavage in the P2 promoter region is induced preferentially by amsacrine but not by demethylepipodophyllotoxins. Thus, selective gene damage among topoisomerase II inhibitors may contribute to differential anticancer activity.

1 To whom requests for reprints should be addressed, at Bldg. 37, Rm. 5C27, National Institutes of Health, Bethesda, MD 20892.

Received 12/27/91. Accepted 3/24/92.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Khobta, C. Carlo-Stella, and G. Capranico
Specific Histone Patterns and Acetylase/Deacetylase Activity at the Breakpoint-Cluster Region of the Human MLL Gene
Cancer Res., April 15, 2004; 64(8): 2656 - 2662.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Gao, E. F. Yamasaki, K. K. Chan, L. L. Shen, and R. M. Snapka
DNA Sequence Specificity for Topoisomerase II Poisoning by the Quinoxaline Anticancer Drugs XK469 and CQS
Mol. Pharmacol., June 1, 2003; 63(6): 1382 - 1388.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
I. Collins, A. Weber, and D. Levens
Transcriptional Consequences of Topoisomerase Inhibition
Mol. Cell. Biol., December 15, 2001; 21(24): 8437 - 8451.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. Binaschi, M. E. Borgnetto, and G. Capranico
Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci
Nucleic Acids Res., September 1, 2000; 28(17): 3289 - 3293.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. L. Strissel, R. Strick, J. D. Rowley, and N. J. Zeleznik-Le
An In Vivo Topoisomerase II Cleavage Site and a DNase I Hypersensitive Site Colocalize Near Exon 9 in the MLL Breakpoint Cluster Region
Blood, November 15, 1998; 92(10): 3793 - 3803.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Binaschi, G. Capranico, L. Dal Bo, and F. Zunino
Relationship between Lethal Effects and Topoisomerase II-Mediated Double-Stranded DNA Breaks Produced by Anthracyclines with Different Sequence Specificity
Mol. Pharmacol., June 1, 1997; 51(6): 1053 - 1059.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
N. Fujii, Y. Yamashita, T. Mizukami, and H. Nakano
Correlation between the Formation of Cleavable Complex with Topoisomerase I and Growth-Inhibitory Activity for Saintopin-Type Antibiotics
Mol. Pharmacol., February 1, 1997; 51(2): 269 - 276.
[Abstract] [Full Text] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
S.V. Razin, R. Hancock, O. Iarovaia, O. Westergaard, I. Gromova, and G.P. Georgiev
Structural-Functional Organization of Chromosomal DNA Domains
Cold Spring Harb Symp Quant Biol, January 1, 1993; 58(0): 25 - 35.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.